Mylan Launches Generic Hepatitis B Treatment

Article

Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.

Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.

This announcement follows the FDA’s final approval of Mylan’s Abbreviated New Drug Application for the product, which is indicated for the treatment of chronic HBV infection associated with evidence of hepatitis B viral replication and active liver inflammation.

Mylan’s version of lamivudine will be available in 100 mg tablets, which had approximately $18.1 million worth of sales in the United States for the 12 months ending September 30, 2014, according to IMS Health.

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.